Immune-Onc Therapeutics Company Profile, Contacts & Intelligence

Biotechnology ResearchPalo Alto, California, United States19 employeesFounded 2016
3 contacts with email or phone data3 with email data2 with phone data
View verified contacts Compare competitors
Employees
19
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 4 visible contacts
Departments
2
Mapped contact coverage

Immune-Onc Therapeutics Overview

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a private, clinical-stage oncology company dedicated to discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1b/2 clinical development for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (a novel bispecific antibody targeting LILRB4 and CD3), and undisclosed immunology and oncology programs. For more information, please visit www.immune-onc.com.

Headquarters
Palo Alto, California, United States
Website
immune-onc.com
Industry
Biotechnology Research
Founded
2016
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Company Email
Available in AeroLeads
in drug development and proven track records of success at leading biotechnology companies.

Immune-Onc Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data and 2 with phone data in the visible sample.
2 departments represented
Visible contacts with email or phone data are mapped to these departments.
General
1
Executive
1

Immune-Onc Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

P
Penny Dong, Phd.
E
B
Barbara Klencke
Board Director
EP
C
Caitlin Gordon Le
Contracts Consultant at Consultant
B
Bj Snider
President/ceo and IT Strategist
EP

Immune-Onc Therapeutics Workforce Composition

Seniority breakdown across 6 visible profiles.

Director
2
Individual contributor
2
Executive
1
Manager
1

Compare Similar Companies to Immune-Onc Therapeutics

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Vertex Pharmaceuticals Biotechnology Research 6.09K View company
BridgeBio Biotechnology Research 778 View company
Nurix Therapeutics Biotechnology 368 View company
Day One Biopharmaceuticals Biotechnology Research 213 View company
ALX Oncology Biotechnology Research 73 View company
Notable Biotechnology Research 34 View company
Ray Therapeutics, Inc. Biotechnology Research 31 View company
Biotech CEO Sisterhood Biotechnology Research 29 View company
Tallac Therapeutics Biotechnology Research 19 View company
Ambagon Therapeutics Biotechnology Research 18 View company